BiotechTube
Home/Gliknik/David Block
DB

David Block

Co-Founder & CEO

Gliknik

Therapeutic Areas

Autoimmune DiseasesOncology

Gliknik Pipeline

DrugIndicationPhase
GL-2045Autoimmune diseases (e.g., Immune Thrombocytopenia)Phase 2
GL-0719Autoimmune diseases (e.g., Cold Agglutinin Disease)Phase 2

Leadership Team at Gliknik

PF
Paul Friedman, M.D.
Director
RS
Raymond Schinazi, Ph.D., D.Sc.
Board Member
View full Gliknik profile